Professor of Medicine
Professor in Surgery
Professor in Pharmacology and Cancer Biology
Member of the Duke Cancer Institute
Campus mail
Duke Box 103861, Durham, NC 27710
Phone
(919) 668-8797
Email address
andrew.armstrong@duke.edu
1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition
Education and Training
- Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
- Internship/Residency, General Internal Medicine, University of Pennsylvania, School of Medicine, 2000 - 2003
- M.Sc., Johns Hopkins University, 2008
- M.D., University of Virginia School of Medicine, 2000
- B.S.E., Duke University, 1996
Grants
- DAROL: Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients
- A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men with Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)
- A PHASE 1, MULTI-CENTER, OPEN-LABEL, DOSE FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CC-94676 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- under protocol number 7051-ONC-101 entitled "A Phase 1 Study of FT-7051 in Men with Metastatic Castration-Resistant Prostate Cancer" (as it may be amended from time to time by Sponsor, the "Protocol"; the performance of the Protocol at all sites is
- Protocol No. 20180146 entitled "A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
- Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer
- Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC
- A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naive Metastatic Castration-Resistant Prostate Cancer
- Study title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
- A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
- ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
- VISION: An International, Prospective, Open-Label, Multicenter, Randomized Phase 3 Study of 177lu-Psma-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interrupting the aberrant cancer development sequence in epithelial cancer progression
- A Phase 2 Study of Nivolumab in combination with either Rucaparib, docetaxel, or enzalutamide in men with Castration-resistant metastaic prostate cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMA
- A Phase II Study of Navarixin (MK-7123) in Combination with Pembrolizumab (MK-3475) in Participants with Selected Advanced/Metastatic Solid Tumors
- A Salvage Trial of AR Inhibition with ADT and Apalutamide with Docetaxel followed by Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (¿STARTAR¿)
- Targeting Convergent Mechanisms of Therapy Resistance, Metastasis, and Immune Evasion with CBP inhibitors
- Targeting convergent mechanisms of castration resistant prostate cancer therapy resistance, metastasis, and immune evasion with AR-LDDs
- NEPC Trial PD-1 Inhibition in Neuroendocrine-like Prostate Cancer (PD-1 Inhibition or Combination Checkpoint Immuntherapy of Neuroedocrine_Like Prostate Cancer
- A Phase 1B, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer who have progressed followinIn
- HOXB13 as a therapeutic target in prostate cancer
- Targeting the p38/Snail/PD-L1 axis in hormone-therapy resistance and metastasis